Efficacy outcomes in Black patients from the ARANOTE trial

EP: 1.The Incidence of Prostate Cancer and Risk of Progression in Black Men

EP: 2.Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men

EP: 3.Representation of Black men with mHSPC in clinical trials

EP: 4.The current treatment landscape of mHSPC

Now Viewing

EP: 5.Efficacy outcomes in Black patients from the ARANOTE trial

EP: 6.Safety data on Black patients from ARANOTE

EP: 7.Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients

EP: 8.Outcomes in Black patients receiving darolutamide plus ADT for mHSPC

EP: 9.Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions

EP: 10.The importance of studying efficacy and safety of treatment in Black patients with mHSPC

EP: 11.Improving diversity in future clinical trials for mHSPC

EP: 12.Remaining unmet needs in diverse populations with mHSPC

ARANOTE Subanalysis Results

Key Themes:

• Ten percent of the ARANOTE study population were Black men.
• Radiologic progression-free survival was similar in Black men (HR, 0.51) vs the overall population (HR, 0.54).
• Time to metastatic castrate-resistant prostate cancer showed a comparable response.
• Complete PSA suppression rates showed 3-fold improvement (59.5% vs 18.2%) with darolutamide.

Key Points for Physicians:

• Darolutamide plus ADT shows comparable efficacy in Black men.
• All major efficacy end points demonstrate consistent benefit across racial groups.
• PSA suppression rate was particularly impressive with the addition of darolutamide.

Notable Insights: The consistency of benefit across multiple clinically meaningful end points provides robust evidence supporting darolutamide’s efficacy in Black men.

Clinical Significance: This subanalysis provides race-specific evidence supporting the use of darolutamide in Black men with metastatic hormone-sensitive prostate cancer, addressing an important gap in prostate cancer treatment evidence.